Media headlines about Champions Oncology (NASDAQ:CSBR) have trended somewhat positive recently, Accern reports. The research group identifies negative and positive media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Champions Oncology earned a news impact score of 0.03 on Accern’s scale. Accern also gave news stories about the biotechnology company an impact score of 47.2458458731504 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Shares of Champions Oncology (NASDAQ CSBR) opened at $4.15 on Friday. The firm has a market capitalization of $45.60, a P/E ratio of -10.64 and a beta of -0.36. Champions Oncology has a fifty-two week low of $2.19 and a fifty-two week high of $4.79.
Champions Oncology (NASDAQ:CSBR) last announced its quarterly earnings results on Thursday, December 7th. The biotechnology company reported ($0.01) EPS for the quarter. The company had revenue of $5.20 million during the quarter. Champions Oncology had a negative net margin of 26.26% and a negative return on equity of 593.68%.
Separately, ValuEngine lowered Champions Oncology from a “hold” rating to a “sell” rating in a report on Wednesday, December 6th.
COPYRIGHT VIOLATION NOTICE: This story was first published by The Lincolnian Online and is owned by of The Lincolnian Online. If you are accessing this story on another site, it was copied illegally and reposted in violation of U.S. and international copyright & trademark law. The original version of this story can be viewed at https://www.thelincolnianonline.com/2018/01/14/champions-oncology-csbr-receives-daily-media-impact-rating-of-0-03-updated-updated.html.
About Champions Oncology
Champions Oncology, Inc is engaged in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. The Company has two business segments: Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). The POS segment provides physicians and patients information to help guide the development of personalized treatment plans.
Receive News & Ratings for Champions Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Champions Oncology and related companies with MarketBeat.com's FREE daily email newsletter.